Status: Not yet recruiting
International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC
The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer. Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.
Participants needed: 361
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Aron Research Foundation EtsUpdated: Feb 19, 2026Locations: 1
Eligibility criteria
Patients aged >18years [+3]
Patients without histologically confirmed diagnosis of UC [+1]